Leadership

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.

Mr. Mueller joined Genmab in July 2025 as Executive Vice President, General Counsel & Chief Legal Officer, responsible for leading and managing the global legal, intellectual property, corporate governance, and global compliance and risk functions.

Before joining Genmab, Mr. Mueller spent more than 20 years at AstraZeneca, living and working in North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding roles as the Deputy General Counsel, International and then as the Deputy General Counsel, Corporate. Prior to AstraZeneca, Mr. Mueller worked as a corporate transactions lawyer at a large national Canadian law firm.

Mr. Mueller holds a Bachelor of Commerce specialist degree from the University of Toronto and a Law Degree (LLB) from Queen’s University.

Anthony Pagano became a non-executive director on the Merus Board of Directors in December 2025.

Mr. Pagano joined Genmab in 2007, was appointed Senior Vice President in 2011, and became Executive Vice President and Chief Financial Officer effective March 1, 2020. Prior to joining Genmab, Mr. Pagano served as Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He began his career at KPMG LLP, where he rose to the position of Manager and provided audit and M&A consulting services to clients ranging from start-ups to Fortune 500 companies across a broad range of industries.

He is a Certified Public Accountant and received a B.S. in Accounting from The College of New Jersey, as well as an M.B.A. from the Stern School of Business at New York University.

Mr. Pagano is also a registered manager of Genmab with the Danish Business Authority.

Martine J. van Vugt, Ph.D. became a non-executive director on the Merus board of directors in December 2025

Dr. van Vugt started her professional career at Genmab in 2001 and was appointed Executive Vice President in 2023 and is currently responsible for Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. She has been active in business development operations since 2011.

From 1998 until joining Genmab in 2001 she studied dendritic cell vaccination therapy as a post-doctoral fellow. Dr. van Vugt holds an M.S. from the University of Wageningen and a Ph.D. from Utrecht University.

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.